Lung CanerSJ-LCCNCT07779005
The Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression
An observational study of Lung Caner, run by Shengjing Hospital at 1 site in China.
Trial summary
Modifiable risk factors, including smoking, alcohol consumption, and diet, play critical roles in cancer progression and patient prognosis. In patients diagnosed with lung cancer, these risk factors not only directly modulate host metabolism and immune regulation, but also exert indirect effects by altering the… Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Caner
- How many people
- 1,500 participants
- Where
- 1 siteChina
- Study dates
- 1 Feb 2019to 31 Dec 2029
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Starting in February 2019, patients with histologically or cytologically confirmed lung cancer who received treatment and follow-up at Shengjing Hospital of China Medical University were enrolled in this study. Clinical and demographic characteristics were extracted from the electronic medical record (EMR) system, lifestyle habits and related exposure data were collected using a validated Food Frequency Questionnaire (FFQ), and high-quality follow-up was conducted on a regular basis.
Who may be able to join
- Patients aged between 18 and 75 years;
- Patients with newly, pathologically confirmed lung cancer;
- Patients diagnosed within the preceding 6 months (time since confirmed diagnosis < 6 months).
Who cannot join
- Individuals aged outside the range of 18-75 years, or those in poor general physical condition who are unable to cooperate with the questionnaire survey;
- Patients with non-primary lung cancer, non-newly diagnosed lung cancer, or those unable to provide definitive pathological confirmation;
- Individuals with severe depression, pregnant women, or those diagnosed with severe cardiovascular/cerebrovascular diseases or severe metabolic dysfunctions affecting the liver, kidneys, or other major organs;
- Individuals unwilling to participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Shengjing Hospital affiliated to China Medical University
Shenyang, Liaoning, 110000
Huanhuan Chen Dr.Chen, +86 18940255489, 20152214@cmu.edu.cn
About this study
Official title: The Shengjing Lung Cancer Cohort (SJ-LCC) Study
Modifiable risk factors, including smoking, alcohol consumption, and diet, play critical roles in cancer progression and patient prognosis. In patients diagnosed with lung cancer, these risk factors not only directly modulate host metabolism and immune regulation, but also exert indirect effects by altering the internal milieu, such as the gut microbiota-potentially exerting a profound impact on long-term clinical trajectories.
Leveraging a well-characterized, longitudinally followed cohort of confirmed lung cancer patients, this study systematically assesses habitual dietary intake, emotional well-being, lifestyle behaviors, and related variables using validated instruments, including the Food Frequency Questionnaire (FFQ). Furthermore, the study integrates multidimensional biomarker profiling across tumor tissue, blood, urine, and fecal samples. By linking exposure profiles, multi-omics data, and long-term clinical follow-up records, this project aims to:
Read more
- Evaluate Prognostic Associations: Investigate the relationships between exposure profiles (e.g., dietary patterns) and long-term clinical outcomes in lung cancer patients, including progression-free survival (PFS), overall survival (OS), and recurrence risk.
- Elucidate Biological Mechanisms: Unravel the underlying mechanisms by which the "exposure profile-multi-omics" axis mediates lung cancer progression, and identify candidate biomarkers with predictive value for clinical prognosis.
Ultimately, this study aims to establish evidence-based healthy lifestyle recommendations for patients and provide healthcare professionals with translational insights to inform precision nutrition and targeted intervention strategies across the continuum of lung cancer care.
- Conditions
- Lung Caner
What is being measured
The primary outcome is the main question the study is designed to answer.
6-Month Progression-Free Survival (PFS) Rate
Measured: 6 months
Overall Survival (OS)
Measured: From enrollment through study completion, up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start1 Feb 2019
- Primary completion30 Dec 2024
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CanerStudies of the same condition, open and under way.
- More trials run by Shengjing HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Shengjing Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Huanhuan Chen, Shengjing Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07779005
- Sponsor's protocol ID
- 2020PS556K
- Acronym
- SJ-LCC
- Status last verified
- Jun 2026
- First submitted
- 19 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Shengjing Lung Cancer Cohort (SJ-LCC) Study
- ClinicalTrials.gov ID
- NCT07779005
- Acronym / sponsor ID
- SJ-LCC / 2020PS556K
- Conditions
- Lung Caner
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Shengjing HospitalUniversity, hospital or other
- Study start
- 1 Feb 2019 (actual)
- Primary completion
- 30 Dec 2024 (actual)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 21 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Modifiable risk factors, including smoking, alcohol consumption, and diet, play critical roles in cancer progression and patient prognosis. In patients diagnosed with lung cancer, these risk factors not only directly modulate host metabolism and immune regulation, but also exert indirect effects by altering the internal milieu, such as the gut microbiota-potentially exerting a profound impact on long-term clinical trajectories.
Leveraging a well-characterized, longitudinally followed cohort of confirmed lung cancer patients, this study systematically assesses habitual dietary intake, emotional well-being, lifestyle behaviors, and related variables using validated instruments, including the Food Frequency Questionnaire (FFQ). Furthermore, the study integrates multidimensional biomarker profiling across tumor tissue, blood, urine, and fecal samples. By linking exposure profiles, multi-omics data, and long-term clinical follow-up records, this project aims to:
- Evaluate Prognostic Associations: Investigate the relationships between exposure profiles (e.g., dietary patterns) and long-term clinical outcomes in lung cancer patients, including progression-free survival (PFS), overall survival (OS), and recurrence risk.
- Elucidate Biological Mechanisms: Unravel the underlying mechanisms by which the "exposure profile-multi-omics" axis mediates lung cancer progression, and identify candidate biomarkers with predictive value for clinical prognosis.
Ultimately, this study aims to establish evidence-based healthy lifestyle recommendations for patients and provide healthcare professionals with translational insights to inform precision nutrition and targeted intervention strategies across the continuum of lung cancer care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Starting in February 2019, patients with histologically or cytologically confirmed lung cancer who received treatment and follow-up at Shengjing Hospital of China Medical University were enrolled in this study. Clinical and demographic characteristics were extracted from the electronic medical record (EMR) system, lifestyle habits and related exposure data were collected using a validated Food Frequency Questionnaire (FFQ), and high-quality follow-up was conducted on a regular basis.
Key inclusion criteria (3 listed)
- Patients aged between 18 and 75 years;
- Patients with newly, pathologically confirmed lung cancer;
- Patients diagnosed within the preceding 6 months (time since confirmed diagnosis < 6 months).
Key exclusion criteria (4 listed)
- Individuals aged outside the range of 18-75 years, or those in poor general physical condition who are unable to cooperate with the questionnaire survey;
- Patients with non-primary lung cancer, non-newly diagnosed lung cancer, or those unable to provide definitive pathological confirmation;
- Individuals with severe depression, pregnant women, or those diagnosed with severe cardiovascular/cerebrovascular diseases or severe metabolic dysfunctions affecting the liver, kidneys, or other major organs;
- Individuals unwilling to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
6-Month Progression-Free Survival (PFS) Rate
Time frame: 6 months
Overall Survival (OS)
Time frame: From enrollment through study completion, up to 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
Related trials for Lung Caner
Not yet recruiting
Percutaneous Pulsed Electric Field Ablation for Early-Stage NSCLC and Lung Oligometastases: A Safety and Efficacy Study
Lung Cancer (NSCLC)
RecruitingPhase 2
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Non-small Cell Lung Caner, KRAS-mutated
RecruitingPhase 2
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Active, not recruitingObservational study
Using e-Nose Technology to Identify Early Lung Cancer
Lung; Node, Lung Cancer
Not yet recruiting
AI-Based DeepGEM Tool for Predicting Gene Mutations in NSCLC Patients: A Randomized Controlled Study
Non Small Cell Lung Caner
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Caner, run by Shengjing Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Huanhuan Chen Dr.Chen (+86 18940255489, 20152214@cmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6-Month Progression-Free Survival (PFS) Rate (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.